Scarica l'app Stockscreener
3.70
2.21%
0.08
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ZNTL Giù?
Forum
Previsione
Precedente Chiudi:
$3.62
Aprire:
$3.62
Volume 24 ore:
575.38K
Relative Volume:
0.30
Capitalizzazione di mercato:
$263.39M
Reddito:
$26.87M
Utile/perdita netta:
$-124.13M
Rapporto P/E:
-2.1291
EPS:
-1.7378
Flusso di cassa netto:
$-125.60M
1 W Prestazione:
+5.11%
1M Prestazione:
+1.93%
6M Prestazione:
+160.56%
1 anno Prestazione:
+168.12%
Intervallo 1D:
$3.595
$3.75
Intervallo di 1 settimana:
$3.47
$4.055
Portata 52W:
$1.13
$6.95
Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile
Nome
Zentalis Pharmaceuticals Inc
Settore
Industria
Telefono
(858) 263-4333
Indirizzo
10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY
Compare ZNTL vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ZNTL
Zentalis Pharmaceuticals Inc
|
3.70 | 263.39M | 26.87M | -124.13M | -125.60M | -1.7378 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-17 | Ripresa | Wells Fargo | Equal Weight |
| 2024-08-12 | Aggiornamento | Wedbush | Underperform → Neutral |
| 2024-06-20 | Downgrade | UBS | Buy → Neutral |
| 2024-06-18 | Downgrade | Jefferies | Buy → Hold |
| 2024-06-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-18 | Downgrade | Wedbush | Neutral → Underperform |
| 2024-06-18 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-11-08 | Downgrade | Wedbush | Outperform → Neutral |
| 2023-11-07 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2022-07-12 | Iniziato | Cowen | Outperform |
| 2022-04-06 | Iniziato | Wells Fargo | Overweight |
| 2021-10-07 | Ripresa | Jefferies | Buy |
| 2021-09-30 | Iniziato | Stifel | Buy |
| 2021-09-29 | Iniziato | Oppenheimer | Outperform |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-01-20 | Iniziato | Wedbush | Outperform |
| 2020-09-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-08-27 | Iniziato | H.C. Wainwright | Buy |
| 2020-04-28 | Iniziato | Guggenheim | Buy |
| 2020-04-28 | Iniziato | Jefferies | Buy |
| 2020-04-28 | Iniziato | Morgan Stanley | Overweight |
| 2020-04-28 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Zentalis Pharmaceuticals Inc Borsa (ZNTL) Ultime notizie
Zentalis Shareholders Back Directors, Auditors and Executive Pay - TipRanks
Zentalis (ZNTL) director awarded 57,100 RSUs, boosting holdings to 307,521 shares - Stock Titan
RSU grant boosts Zentalis (ZNTL) director Jan Skvarka's holdings - Stock Titan
Zentalis Pharmaceuticals (ZNTL) director granted 57,100 restricted stock units - Stock Titan
Zentalis (ZNTL) director Enoch Kariuki granted 57,100 restricted stock units - Stock Titan
Zentalis Pharmaceuticals (ZNTL) director awarded 57,100 RSUs - Stock Titan
Zentalis (ZNTL) investors elect directors and ratify Ernst & Young at 2026 meeting - Stock Titan
Zentalis Pharmaceuticals Inc (ZNTL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Zentalis Pharmaceuticals Inc (ZNTL) Institutional Confidence - TradingKey
Zentalis Pharmaceuticals Inc (ZNTL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Zentalis Pharmaceuticals Inc (ZNTL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Zentalis Pharmaceuticals Inc (ZNTL) Valuation: PE, PB & Fair Value Analysis - TradingKey
Zentalis Pharmaceuticals Inc (ZNTL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Zentalis Pharmaceuticals Inc (ZNTL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Zentalis Pharmaceuticals Inc (ZNTL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Guggenheim Increases Zentalis Price Target, Sparking Investor Interest - timothysykes.com
ZNTL Stock Rallies To Near 22-Month Highs – An Analyst Sees Further 56% Upside After A Crucial Trial Update - Stocktwits
ZENTALIS PHARMACEUTICALS INC (ZNTL) Stock Chart - ChartMill
Number of shareholders of Zentalis Pharmaceuticals, Inc. – NASDAQ:ZNTL - TradingView
Zentalis Pharmaceuticals (ZNTL) Consolidates Near Support as Biotech Sector Awaits CatalystsFloat Adjusted Cap - newsline.com
Zentalis Pharmaceuticals Insider Sellers Vindicated After 10% Drop - simplywall.st
ZNTL Should I Buy - Intellectia AI
Zentalis Pharmaceuticals (ZNTL) Jefferies Global Healthcare Conference 2026 Summary - Quartr
ZNTL: Azenosertib shows promise in PROC, with strong efficacy and future combination plans underway - TradingView
Zentalis grants 191,000 stock options to new hires under Nasdaq inducement rule. - Pluang
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Zentalis Pharmaceuticals Expands Board, Appoints New Director - TipRanks
Zentalis strengthens commercial leadership with appointments of Shannon Campbell to board of directors and Sarah Kelly as SVP of commercial strategy - marketscreener.com
Zentalis adds board member, commercial executive ahead of trial data - Investing.com
Zentalis adds board member, commercial executive ahead of trial data By Investing.com - Investing.com Canada
Zentalis (ZNTL) director Shannon Campbell receives 114,200-share RSU award - Stock Titan
Zentalis Pharmaceuticals (ZNTL) expands board, awards RSUs to new director - Stock Titan
Zentalis (ZNTL) director Campbell Shannon files routine Form 3 insider report - Stock Titan
Zentalis Strengthens Commercial Leadership with - GlobeNewswire
ZNTL: Azenosertib shows promising efficacy and safety in ovarian cancer, with pivotal data expected this year - TradingView
Zentalis Pharmaceuticals Inc at TD Cowen Oncology Innovation Summit (Virtual) Transcript - GuruFocus
Zendesk Inc (ZEN) - Minichart
H.C. Wainwright Maintains Zentalis Pharmaceuticals(ZNTL.US) With Buy Rating, Maintains Target Price $10 - Moomoo
H.C. Wainwright reiterates Zentalis stock rating on ovarian cancer data By Investing.com - Investing.com Canada
Zentalis Pharmaceuticals (ZNTL) Faces Resistance Near $4.26 After Recent PullbackRSI Overbought Alerts - newsline.com
Zentalis Pharmaceuticals Presents Promising Phase 1b MUIR Trial Results of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026 9 - Minichart
Zentalis to present ovarian cancer trial data at ASCO meeting By Investing.com - Investing.com Australia
Phase 1b ovarian cancer data for Zentalis (NASDAQ: ZNTL) azenosertib combo - Stock Titan
Zentalis Pharmaceuticals Announces Promising Phase 1b Results for Azenosertib Plus Paclitaxel in Ovarian Cancer at ASCO 2026 - Quiver Quantitative
Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026 - GlobeNewswire
Zentalis Pharmaceuticals (ZNTL) price target increased by 19.05% to 5.83 - MSN
ZNTL SEC FilingsZentalis Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Zentalis Pharmaceuticals (ZNTL) Stock: Down -10.37%, Support Test at $3.45 2026-05-18Golden Cross - The Legal Advocate
What's behind the surge in Zentalis stock? - MSN
Immunome Inc stock (US45254C1062): oncology deal momentum keeps biotech in focus - AD HOC NEWS
ZNTL Stock Price, Quote & Chart | ZENTALIS PHARMACEUTICALS INC (NASDAQ:ZNTL) - ChartMill
Zentalis Pharmaceuticals Inc Azioni (ZNTL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.74%
1.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):